High-dose-rate brachytherapy MRI-guided Localized prostate cancer
Conditions
Interventions
High-dose-rate brachytherapy will be performed for patients with low to intermediate risk prostate carcinoma. The treatment will include a single fraction of 19 Gy. High-dose-rate brachytherapy will b
Sponsors
University Medical Center Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age =65 years; 2. Patients with prostate cancer, T stage =T2c, Gleason =7, Prostate Specific Antigen (PSA) <10 ng/ml; 3. Tumour location technically feasible for brachytherapy; 4. Karnofski score =70; 5. Written informed consent; 6. Fit for spinal anaesthesia.
Exclusion criteria
Exclusion criteria: 1. Previous pelvic radiotherapy for another malignancy; 2. Previous surgery or transurethral resection of the prostate; 3. Prostate cancer recurrence; 4. Patients who meet exclusion criteria for MRI following the protocol of the radiology department of the UMC Utrecht; 5. International Prostate Symptom Score (IPSS) >15; 6. Anticoagulant administration continuously required; 7. Discongruence between prostate biopsies and MR imaging.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of gastro-intestinal and/or urogenital toxicity, aiming for less than 5% grade =3 toxicity. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To determine the technical feasibility of MRI guided focal high-dose rate brachytherapy for localized prostate cancer; 2. Quality of life; 3. Biochemical disease-free survival. | — |
Contacts
Public ContactJ.R.N. van der Voort van Zyp
UMC Utrecht, Department of Radiotherapy
Outcome results
None listed